View ValuationGB Sciences 将来の成長Future 基準チェック /06現在、 GB Sciencesの成長と収益を予測するのに十分なアナリストの調査がありません。主要情報n/a収益成長率n/aEPS成長率Pharmaceuticals 収益成長14.4%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジNone最終更新日n/a今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Jul 12Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of LethbridgeGb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents.お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Jan 20GB Sciences, Inc., Annual General Meeting, Mar 09, 2023GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Mar 30Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research ArticleGb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors.お知らせ • Mar 03GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary CystitisGb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.お知らせ • Jan 13An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million.An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term. An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021.お知らせ • Sep 15GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related HyperinflammationGb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients.お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.お知らせ • Nov 26GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of DirectorsGB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests.お知らせ • Sep 19Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX).Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level. Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017.お知らせ • Aug 18GB Sciences, Inc. announced delayed 10-Q filingOn 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.お知らせ • Aug 14GB Sciences, Inc. announced delayed annual 10-K filingOn 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC. このセクションでは通常、投資家が会社の利益創出能力を理解する一助となるよう、プロのアナリストのコンセンサス予想に基づく収益と利益の成長予測を提示する。しかし、GB Sciences は十分な過去のデータを提供しておらず、アナリストの予測もないため、過去のデータを外挿したり、アナリストの予測を使用しても、その将来の収益を確実に算出することはできません。 シンプリー・ウォール・ストリートがカバーする企業の97%は過去の財務データを持っているため、これはかなり稀な状況です。 業績と収益の成長予測OTCPK:GBLX - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/20240-1-1-1N/A9/30/2024N/A-1-1-1N/A6/30/2024N/A-2-1-1N/A3/31/2024N/A-2-1-1N/A12/31/2023N/A-4-1-1N/A9/30/2023N/A-4-1-1N/A6/30/2023N/A-4-1-1N/A3/31/2023N/A-4-2-2N/A12/31/2022N/A-5-2-2N/A9/30/2022N/A0-2-2N/A6/30/2022N/A0-2-2N/A3/31/2022N/A0-2-2N/A12/31/2021N/A3-2-2N/A9/30/2021N/A-2-3-3N/A6/30/2021N/A-2-3-2N/A3/31/2021N/A-3-2-2N/A12/31/2020N/A-7-2-1N/A9/30/2020N/A-3-1-1N/A6/30/2020-1-3-2-2N/A3/31/2020N/A-4-5-4N/A12/31/20191-5-7-6N/A9/30/20191-11-8-7N/A6/30/20193-18-9-9N/A3/31/20193-21-12-10N/A12/31/20184-26-15-12N/A9/30/20184-30N/A-13N/A6/30/20184-25N/A-13N/A3/31/20183-23N/A-12N/A12/31/20172-16N/A-10N/A9/30/20170-12N/A-8N/A6/30/20170-12N/A-6N/A3/31/2017N/A-10N/A-4N/A12/31/2016N/A-9N/A-4N/A9/30/2016N/A-7N/A-4N/A6/30/2016N/A-7N/A-3N/A3/31/2016N/A-7N/A-4N/A12/31/2015N/A-9N/A-3N/A9/30/2015N/A-9N/A-3N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: GBLXの予測収益成長が 貯蓄率 ( 3.5% ) を上回っているかどうかを判断するにはデータが不十分です。収益対市場: GBLXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です高成長収益: GBLXの収益が今後 3 年間で 大幅に 増加すると予想されるかどうかを判断するにはデータが不十分です。収益対市場: GBLXの収益がUS市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: GBLXの収益が年間20%よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。一株当たり利益成長率予想将来の株主資本利益率将来のROE: GBLXの 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/11 10:23終値2026/05/11 00:00収益2024/12/31年間収益2024/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋GB Sciences, Inc. 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
お知らせ • Nov 20GB Sciences, Inc. announced delayed 10-Q filingOn 11/19/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Feb 13GB Sciences, Inc. announced delayed 10-Q filingOn 02/12/2025, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 15GB Sciences, Inc. announced delayed 10-Q filingOn 08/14/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 07/01/2024, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 15GB Sciences, Inc. announced delayed 10-Q filingOn 11/14/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Jul 12Gb Sciences' First-In-Class Parkinson's Disease Therapy Successfully Completes Dose Response Study At the University of LethbridgeGb Sciences, Inc. has successfully completed a dose response study in rodents at the University of Lethbridge that supports Gb Sciences' cannabinoid-based therapy for Parkinson's disease. The study has established dose ranges and the corresponding times to onset and duration of action in a rodent model. In addition to the dosage range findings, this study demonstrated that Gb Sciences' Parkinson's disease formulations were well tolerated, and there were no adverse effects. As early as next year, Gb Sciences plans on filing an Investigational New Drug Application to begin first-in-human clinical trials. As the second most common neurodegenerative disease, the market for Parkinson's disease (PD) treatments is expected to grow to $12.8 billion by 2028. The dose response study in rodents performed at the University of Lethbridge helps to establish the correct dosing of Gb Sciences' cannabinoid-containing Parkinson's formulations for a first-in-human trial. Dr. Robert Sutherland, Ph.D., FRSC, Professor and Chair of the Department of Neuroscience at the University of Lethbridge, Board of Governors Research Chair in Neuroscience, and Director of the Canadian Centre for Behavioral Neuroscience, used deep learning models to analyze the rich data sets from their "Home Cage Small World" behavioral assessments of rodents with video cameras and Artificial Intelligence, using a system developed by Neurocage Systems Ltd. Future studies confirming the mechanism of action of these cannabinoid-based Parkinson's formulations are planned with Dr. Sutherland's research group at the University of Lethbridge using their behavioral measurement methods for rodents.
お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2023, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Jan 20GB Sciences, Inc., Annual General Meeting, Mar 09, 2023GB Sciences, Inc., Annual General Meeting, Mar 09, 2023, at 10:00 Pacific Standard Time. Agenda: To consider and elect three directors to serve on Board of Directors and until each of their successors has been duly elected and qualified, unless such individuals shall sooner die, resign or be removed; to approve an amendment to articles of incorporation to increase the number of shares of stock Board of Directors is authorized to issue from 600,000,000 shares to 950,000,000 shares; to ratify the appointment of Assurance Dimensions as independent registered public accounting firm for the fiscal year ended March 31, 2023; and to transact such other business as may properly come before the Meeting or any postponement or adjournment thereof.
お知らせ • Jul 01GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2022, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Mar 30Gb Sciences' Nanoparticle Encapsulation Technology Improves the Efficacy of Terpenes for Use in Chronic Pain Formulations as Demonstrated in New Research ArticleGb Sciences, Inc. announced that their sponsored study investigating the effect of nanoparticle encapsulation of three cannabis-based terpenes on their potential efficacy in pain management was published in the International Journal of Pharmaceutics on March 25. For the Gb Sciences-sponsored study, researchers at the University of Seville in Spain have developed time-released, oral nanoparticles to deliver Gb Sciences' patent-protected chronic pain formulations, which are based on synergistic mixtures of terpenes. Terpenes are normally highly volatile, highly lipophilic molecules that are difficult to formulate into stable drug products, so Gb Sciences and their colleagues believe that nanocarriers can improve their stability, solubility, and bioavailability. In the U.S. alone, chronic pain represents an estimated health burden of between $560 and $650 billion dollars, and an estimated 20.4% of U.S. adults suffer from chronic pain that significantly decreases their quality of life. Despite the widespread rates of addiction and death, opioids remain the standard of care treatment for most people with chronic pain. Concerns over those issues have made novel chronic pain treatments such as Gb Sciences' therapies an important and promising field of research and development. The Gb Sciences-sponsored study tested the effect of poly(lactide-co-glycolide) nanoparticles containing the three terpenes versus the effect of free terpenes in a cell model with TRPV1 receptors, which are known pain receptors. The study found that the encapsulated terpene nanoparticles produced significantly higher calcium responses alone or in combinations versus the free terpenes alone or in combinations. The elevated calcium responses through the TRPV1 channels indicate greater activation of these pain receptors, which can have an analgesic effect via desensitization of these important pain receptors.
お知らせ • Mar 03GB Sciences, Inc. Announces Grant of U.S. Patent for Cannabinoid-Containing Treatment for Advanced Heart Disease, TRPV1-Receptor-Associated Hearing Loss and Urinary CystitisGb Sciences, Inc. has been issued a new patent by the U.S. Patent and Trademark Office (USPTO) for a cannabinoid-containing mixture designed to treat cardiac hypertrophy, often present in advanced heart disease. Gb Sciences' newly issued patent also covers the use of these receptor-targeted formulations for the treatment of TRPV1-receptor-associated hearing loss and urinary cystitis. Despite multiple categories of prescription heart medications on the market, heart disease remains the leading cause of death in the United States for people of most racial and ethnic groups. Alternative therapeutic approaches are still needed, especially for the treatment of advanced heart disease.
お知らせ • Jan 13An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million.An unknown buyer acquired Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) for $8 million on December 31, 2021. The sale, valued at $8 million, will allow Gb Sciences to reduce outstanding debt and bolster its cash position. The proceeds from this sale include $1.2 million in cash, $3.8 million in immediate debt and liabilities reduction, and a $3 million interest-bearing note payable to Gb Sciences by the buyer over a three-year term. An unknown buyer completed the acquisition of Las Vegas cannabis facility of GB Sciences, Inc. (OTCPK:GBLX) on December 31, 2021.
お知らせ • Sep 15GB Sciences Achieves Positive Proof-of-Concept Results for Their Cytokine Release Syndrome Therapies Designed to Suppress COVID-Related HyperinflammationGb Sciences, Inc. received positive proof-of-concept data from a human immune cell model supporting their proprietary cannabinoid-containing complex mixtures (CCCM) designed for the suppression of COVID-related cytokine release syndromes (CRS) while preserving key anti-viral immune responses. Based on this new positive proof-of-concept data, Gb Sciences converted their provisional patent application entitled, "CANNABINOID-CONTAINING COMPLEX MIXTURES FOR THE TREATMENT OF CYTOKINE RELEASE SYNDROME WHILE PRESERVING KEY ANTI-VIRAL IMMUNE REACTIONS" to a nonprovisional patent application on August 18, 2021. The best-performing cannabinoid-containing complex mixtures will be further developed in preparation for clinical studies to evaluate their anti-inflammatory potential in the treatment of severely ill COVID-19 patients contending with Cytokine Release Syndrome (CRS) and associated hyperinflammatory conditions, such as macrophage activation syndrome (MAS) and acute respiratory distress syndrome (ARDS). CRS, MAS, and ARDS are the leading causes of death in COVID-19 patients.
お知らせ • Jul 02GB Sciences, Inc. announced delayed annual 10-K filingOn 06/30/2021, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.
お知らせ • Nov 26GB Sciences, Inc. Announces Resignation of Leslie Bocskor as A Member of the Board of DirectorsGB Sciences, Inc. announced that effective November 23, 2020, Mr. Leslie Bocskor resigned his position as a member of the board of directors of the Company to pursue other business interests.
お知らせ • Sep 19Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX).Cesar Cordero-Kruger acquired an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017. GB Sciences did not receive any consideration in the transaction but was relieved of any obligation to fund the losses of GB Sciences Puerto Rico going forward. As the result of the transaction, GB Sciences deconsolidated the assets, liabilities and noncontrolling interests of GB Sciences Puerto Rico since its ownership interest was reduced to a non-controlling level. Cesar Cordero-Kruger completed the acquisition of an additional 17% stake in GB Sciences Puerto Rico, LLC from GB Sciences, Inc. (OTCPK:GBLX) during the third quarter of 2017.
お知らせ • Aug 18GB Sciences, Inc. announced delayed 10-Q filingOn 08/17/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-Q by the deadline required by the SEC.
お知らせ • Aug 14GB Sciences, Inc. announced delayed annual 10-K filingOn 08/13/2020, GB Sciences, Inc. announced that they will be unable to file their next 10-K by the deadline required by the SEC.